Login to Your Account

Exelixis Pops on Phase III Cabo Data, but Analysts Wary

By Trista Morrison

Tuesday, October 25, 2011
Shares of Exelixis Inc. popped 24.2 percent Monday thanks to impressive results from a Phase III trial of cabozantinib in medullary thyroid cancer (MTC), but analysts remained cautious about the drug's potential in the larger prostate cancer indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription